Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Celgene-CELG -- Ignore unavailable to you. Want to Upgrade?

To: Miljenko Zuanic who wrote (406)	2/11/2000 9:30:00 AM
From: biowa	Read Replies (2) \| Respond to of 804

Miljenko, Pssssss...we are in winter sleep* mode...bzzzz* For when you wake-up <g>: WARREN, N.J., Feb. 10 /PRNewswire/ -- Celgene Corporation (Nasdaq: CELG) today announced that it has priced a public offering of 3,000,000 shares of its Common Stock at $101.00 per share. Of the shares offered, 2,484,000 shares are being sold by Celgene for its own account. The remaining 516,000 shares are being sold on behalf of John Hancock Life Insurance Company and its affiliates. Celgene has granted to the underwriters an option to purchase an additional 450,000 shares of common stock to cover over-allotments. Celgene intends to use the net proceeds from the offering for the further commercialization and clinical development of THALOMID(R), the further development of its oncology and immunology programs, the further development of its chiral products and general corporate purposes. J.P. Morgan & Co. is the bookrunner of the offering. J.P. Morgan & Co. and Prudential Vector Healthcare are acting as joint lead managers of the offering and U.S. Bancorp Piper Jaffray is acting as a co-manager. The offering is expected to close on February 16, 2000. Information about this offering is available in the prospectus filed with the Securities and Exchange Commission.